

Special Issue

Chemical Molecules Isolated from Natural Sources and Synthetic Drug Discovery for Liver and Kidney Disease

Message from the Guest Editors

This Special Issue of *Biomedicines*, “Chemical molecules isolated from natural sources and Synthetic Drug Discovery for Liver and Kidney Disease”, aims to provide a comprehensive, multidisciplinary overview of the current knowledge in this field. We invite authors to submit original research articles and reviews that focus on the biochemical functions and therapeutic potential of the chemical molecules isolated from natural sources and synthetic drug discovery. Potential topics include, but are not limited to, the following:

- Drug discovery using chemical molecules isolated from natural sources;
- Synthetic drug discovery;
- Liver disease;
- Kidney disease;
- Metabolic/signaling pathways;
- Immuno-regulatory function;
- Reactive oxygen/nitrogen species;
- Metabolic processes;
- Biomarkers;
- Inflammation;
- Recent advances in liver and kidney therapies, based on protection with chemical molecules isolated from natural sources and synthetic drug discoveries.
- Recent advances in liver and kidney therapies, after symptomatic COVID-19, based on protection with the chemical molecules isolated from natural sources and synthetic drug discoveries.

Guest Editors

Dr. Yanka D. Karamalakova

Medical Faculty, Trakia University, Stara Zagora, Bulgaria

Dr. Ekaterina Georgieva

Medical Faculty, Trakia University, Stara Zagora, Bulgaria

Deadline for manuscript submissions

closed (31 August 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/200916

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).